Welcome to the latest edition of our weekly EuroBiotech Report. Indivior (LON:INDV) took a big step toward bringing its once-a-month opioid dependence drug to market. The Reckitt Benckiser (LON:RB) spinout reported Phase III data on the program, sending its stock up 15% and positioning it to snag an approval by the end of 2017. Johnson & Johnson ($JNJ) and Genmab (CPH:GEN) are hoping to get their latest trip to FDA wrapped up much sooner. The pair are waiting on a priority review decision that could lead to the label for Darzalex being expanded in the coming months. Zealand Pharma (CPH:ZEAL) is also gearing up for talks with FDA. The Danish drugmaker wants to meet with the regulator to discuss Phase II data on its rival to Novo Nordisk’s ($NVO) GlucaGen. Basilea Pharmaceutica (SWX:BSLN) rejigged its early-stage pipeline, dropping an inhaled antibiotic while expanding a trial of its small molecule tumor checkpoint controller. Cancer Research UK began a Phase I/II bladder cancer trial of Astex Pharmaceuticals’ DNA methyltransferase inhibitor. And more.